• FY25 revenue of $111.5m, up 21.6% (+19.5% in constant currency)
• EBITDA of $9.2m, exceeding guidance range of $7-9m
• Positive FY25 net cash inflow from operating activities of $4.8m

SomnoMed Limited (ASX 'SOM'), the leading company in the provision of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (OSA), has reported its FY25 full year results for the period ended 30 June 2025 (FY25). The company experienced double-digit growth across all regions, with North America delivering a stellar performance and contributing nearly 40% of the company's revenue. Europe remained the largest region, with 55% of revenue, driven by strong performances in France, Germany, and Sweden. The company exceeded market guidance, reporting FY25 revenue of $111.5m, up 21.6% (+19.5% in constant currency), and EBITDA of $9.2m, exceeding the guidance range of $7-9m. Gross margin remained consistent at 60%, and the company reported positive FY25 net cash inflow from operating activities of $4.8m, positive free cash flow of $0.8m, and a cash balance of $17.3m at 30 June 2025. During the year, the company focused on increasing capacity to meet demand, reducing backlog to negligible levels, and commencing work to further expand capacity to support future growth. The company also achieved the milestone of treating 1 million patients, becoming the only oral appliance company to have reached this milestone.

For FY26, the company provides guidance for revenue of between $119m and $126m, EBITDA of between $10m and $12m, and capex of between $6m and $8m.

Looking ahead, the company will remain focused on sustainable revenue and margin growth, expanding manufacturing capacity to support growing demand, and continuing the development of its Rest Assure compliance tracking system.